Chelation Therapy

Complementary and Integrative Therapies for Cardiovascular Disease

Volumn , Issue , 2005, Pages 288-299

  Frishman, William H ^a   Wolff, Andrew I ^b  

^a WESTCHESTER MEDICAL CENTER   (United States)

^b STRONG MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 22044456466     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-03002-1.50021-5     Document Type: Chapter

References (70)

1. Cranton EM A textbook on EDTA chelation therapy. J Adv Med 1989, 2:1-416.
2. Diagnostic and therapeutic technology assessment: chelation therapy. JAMA 1983, 250:672.
3. Elihu N, Anandasabapathy S, Frishman WH Chelation therapy in cardiovascular disease: ethylenediaminetetraacetic acid and deferoxamine. J Clin Pharmacol 1998, 38:101-105.
4. Clarke NE, Clarke CN, Mosher RF The "in vivo" dissolution of metastatic calcium: an approach to atherosclerosis. Am J Med Sci 1955, 229:142.
5. Blumer W, Cranton EM Ninety percent reduction in cancer mortality after chelation therapy with EDTA. J Adv Med 1989, 2:183-187.
6. Olszewer E, Carter JC EDTA chelation therapy in chronic degenerative disease. Med Hypotheses 1988, 27:41-49.
7. Olszewer E, Carter JP EDTA chelation therapy a retrospective study of 2870 patients. J Adv Med 1989, 2:197-211.
8. Clarke NE, Clarke C, Mosher R Treatment of angina pectoris with disodium ethylene tetraacetic acid. Am J Med Sci 1956, 232:654-666.
9. Morgan K Myocardial ischemia treated with nutrients and intravenous EDTA chelation: report of two cases. J Adv Med 1991, 4:47-56.
10. Cranton EM: Protocol of the American College of Advancement in Medicine for the Safe and Effective Administration of EDTA Chelation Therapy, Laguna Hills, CA, 1989, American College of Advancement in Medicine.
11. Godfrey ME EDTA chelation as a treatment of arteriosclerosis. NZ Med J 1990, 103:162-163.
12. van-Rij AM, Solomon C, Parker SG, Hopkins WG Chelation therapy for intermittent claudication: a double-blind, randomized, controlled trial. Circulation 1994, 90:1194-1199.
13. Soffer A Chelation therapy for atherosclerosis. JAMA 1975, 233:1206-1207.
14. Wirebaugh SR, Geraets DR Apparent failure of edetic acid chelation therapy for treatment of coronary atherosclerosis. DICP 1990, 24:22-25.
15. Rathmann KL, Golithly L Chelation therapy of atherosclerosis. Drug Intell Clin Pharm 1984, 8:1000-1003.
16. Eisenberg, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1998, 280:1569-1575.
17. Magee P Chelation treatment for atherosclerosis. Med J Aust 1985, 142:514-515.
18. Boyle AJ, Clarke NE, Mosher RE, McCann DS Chelation therapy in circulatory and sclerosing diseases. Fed Proc 1961, 29:243-251.
19. Olszewer E, Sabbag FC, Carter JA A pilot double-blind study of sodium-magnesium EDTA in peripheral vascular disease. J Natl Med Assoc 1990, 82:173-177.
20. Ross R The pathogenesis of atherosclerosis: an update. N Engl J Med 1986, 314:488-500.
21. Peerscke EL, Grant RA, Zucker MB Decreased association of 45 calcium with platelets unable to aggregate due to thrombasthenia or prolonged calcium deprivation. Br J Haematol 1980, 46:247-256.
22. Kindness G, Frackelton JP Effect of ethylene diamine tetraacetic acid (EDTA) on platelet aggregation in human blood. J Adv Med 1989, 2:519-530.
23. Fitzgerald LA, Phillips DR Calcium regulation of the platelet membrane glycoprotein IIb/IIIa complex. J Biol Chem 1985, 260:11366-11374.
24. Cranton EM, Frackelton JP Free radical pathology in age-associated diseases: treatment with EDTA chelation, nutrition and antioxidants. J Hol Med 1984, 6:6-37.
25. Deucher DP EDTA chelation: an antioxidant strategy. J Adv Med 1988, 1:182-190.
26. Walker M, Gordon G: The chelation answer. How to prevent hardening of the arteries and rejuvenate your cardiovascular system, New York, 1982, M Evans.
27. Mallette LE, Hollis BW, Dunn K, et al. Ten weeks of intermittent hypocalcemic stimulation does not produce functional parathyroid hyperplasia. Am J Med Sci 1991, 302(3):138-141.
28. Perry HM, Schroeder HA Depression of cholesterol levels in human plasma following ethylenediamine tetraacetate and hydralazine. J Chron Dis 1995, 2:520-533.
29. Rudolph CJ, McDonagh EW, Barber RK Effect of EDTA chelation on serum iron. J Adv Med 1991, 4:39-45.
30. Lamar CP Chelation therapy of occlusive arteriosclerosis in diabetic patients. Angiology 1964, 15:379-395.
31. Lamar CP Chelation endarterectomy for occlusive atherosclerosis. J Am Geriatr Soc 1966, 14:272-294.
32. Casdorph HR, Farr CH EDTA chelation therapy, III: treatment of peripheral arterial occlusion, an alternative to amputation. J Hol Med 1983, 5:3.
33. Guldager B, Jelnes R, Jorgensen SJ, et al. EDTA treatment of intermittent claudication: a double-blind, placebo-controlled study. J Intern Med 1992, 231:261-267.
34. Sloth-Nielsen J, Guldager B, Mouitzen C, et al. Arteriographic findings in EDTA chelation therapy on peripheral arteriosclerosis. Am J Surg 1991, 162:122-125.
35. Kitchell JR, Palmon F, Aytan N, Meltzer LE The treatment of coronary artery disease with disodium EDTA: a reappraisal. Am J Cardiol 1963, 11:501.
36. Hancke C, Flytlie K Benefits of chelation therapy in atherosclerosis: a retrospective study of 470 patients. J Adv Med 1993, 6:161.
37. Van der Schaar P Exercise tolerance in chelation therapy. J Adv Med 1989, 2:563.
38. Soffer A, Toribara T, Sayman A Myocardial responses to chelation. Br Heart J 1961, 23:690-694.
39. Soffer A Chelation clinics: an abuse of the physician's freedom of choice. Arch Intern Med 1984, 144:1741-1742.
40. Chappell LT, Stahl JP The correlation between EDTA chelation therapy and improvement in cardiovascular function: a meta-analysis. J Adv Med 1993, 6:139-160.
41. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina, a summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Chronic Stable Angina). J Am Coll Cardiol 2003, 41:159-168.
42. Riordan HD, Cheraskin E, Dirks M, Schultz M, Brizendine P Electrocardiographic changes associated with EDTA chelation therapy. J Adv Med 1988, 1:191-194.
43. Riordan HD, Cheraskin E, Dirks M, et al. EDTA chelation/hypertension study: Clinical patterns as judged by the Cornell Medical Index questionnaire. J Ortho Med 1989, 4:91-95.
44. Knudtson ML, Wyse DG, Galbraith PD, et al. Chelation therapy for ischemic heart disease: a randomized, controlled trial. JAMA 2002, 287:481-486.
45. Anderson TJ, Hubacek J, Wyse G, Knudtson ML Effect of chelation therapy on endothelial function in patients with coronary artery disease: PATCH substudy. J Am Coll Cardiol 2003, 41:420-425.
46. Laslett L Chelation theapy: new proof of lack of efficacy. Prev Cardiol Spring 2002, 92-93.
47. Holden C Alternative medicine: NIH trial to test chelation therapy. Science 2002, 297:1109.
48. NIH: NIH Launches large clinical trial on EDTA chelation therapy for coronary artery disease, . http://nccam.nih.gov/news/2002/chelation/pressrelease.htm.
49. Clinical Trial: 4rial to assess chelation therapy. www.clinicaltrials.gov/ct.
50. Quan H, Ghali WA, Verhoef MJ, et al. Use of chelation therapy after coronary angiography. Am J Med 2001, 111:686-691.
51. Frishman WH Chelation therapy for coronary artery disease: panacea or quackery? (editorial). Am J Med 2001, 111:729-730.
52. Frishman WH, Retter A, Misailidis J, et al. Innovative pharmacologic approaches to the treatment of myocardial ischemia. Cardiovascular Pharmacothera-peutics 2003, 655-690. McGraw Hill, New York. ed 2. W.H. Frishman, E.H. Sonnenblick, D.A. Sica (Eds.).
53. Salonen JT, Nyyssonen K, Korpela H, et al. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992, 86:803-811.
54. Morrison HI, Semenciw RM, Mao Y, Wigle DT Serum iron and risk of fatal acute myocardial infarction. Epidemiology 1994, 5:243-246.
55. Haidari M, Javadi E, Sanati A, et al. Association of increased ferritin with premature coronary stenosis in men. Clin Chem 2001, 47:1666-1672.
56. Tuomainen TP, Kontula K, Nyyssonen K, et al. Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282 Tyr mutation: a prospective cohort study in men in eastern Finland. Circulation 1999, 100:1274-1279.
57. Maza SR, Frishman WH Therapeutic options to minimize free radical damage and thrombogenicity in ischemic/reperfused myocardium. Med Clin North Am 1988, 72:227-242.
58. Pratico D, Pasin M, Barry OP, et al. Iron-dependent human platelet activation and hydroxyl radical formation: involvement of protein kinase C. Circulation 1999, 99(24):3118-3124.
59. Gaenzer H, Marschang P, Sturm W, et al. Association between increased iron stores and impaired endothelial function in patients with hereditary hemochromatosis. J Am Coll Cardiol 2002, 40:2189-2194.
60. Solymoss BC, Marcil M, Gilfix BM, et al. The place of ferritin among risk factors associated with coronary artery disease. Coron Artery Dis 1994, 5(3):231-235.
61. Magnusson MK, Sigfusson N, Sigvaldason H, et al. Low iron-binding capacity as a risk factor for myocardial infarction. Circulation 1994, 89:102-108.
62. Voest EE, Vreugdenhil G, Marx JJM Iron-chelating agents in non-iron overload conditions. Ann Intern Med 1994, 120:490-499.
63. Porreca E, Ucchino S, Di Febbo C, et al. Antiproliferative effect of desferrioxamine on vascular smooth muscle cells in vitro and in vivo. Arterioscler Thromb 1994, 14:299-304.
64. DeBoer D, Clark R Iron chelation in myocardial preservation after ischemia-reperfusion injury: the importance of pretreatment and toxicity. Ann Thorac Surg 1992, 53:412-418.
65. Ambrosio G, Zweier J, Jacobus W, et al. Improvement of postischemic myocardial function and metabolism induced by administration of deferoxamine at the time of reflow: the role of iron in the pathogenesis of reperfusion injury. Circulation 1987, 76:906-915.
66. Menasche P, Antebi H, Alcindor LG, et al. Iron chelation by deferoxamine inhibits lipid peroxidation during cardiopulmonary bypass in humans. Circulation 1990, 82(Suppl IV). IV390-396.
67. Reddy BR, Wynne J, Kloner RA, Przyklenk K Pretreatment with the iron chelator deferoxamine on transferrin receptors: the cell cycle and growth rates of human leukaemic cells. Cardiovasc Res 1991, 25:711.
68. Rudolph CJ, McDonagh EW, Barber RK Effect of EDTA chelation on serum iron. J Adv Med 1991, 4:39-45.
69. Anderson LJ, Wonke B, Prescott E, et al. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002, 360:516-520.
70. Frishman WH, Sonnenblick EH. Environmental factors in cardiac hypertrophy and failure. In Molecular Mechanisms of Cardiac Hypertrophy and Failure, edited by Walsh RA: Lancaster UK, Parthenon Publishing. In press.